April 26, 2018 / 11:53 AM / a month ago

BRIEF-Fujirebio Says Entered Into Agreement With Janssen Pharmaceuticals

April 26 (Reuters) - Miraca Holdings Inc:

* FUJIREBIO SAYS ENTERED INTO AGREEMENT WITH JANSSEN PHARMACEUTICALS TO DEVELOP & COMMERCIALIZE AMYLOID Β 42/40 RATIO ASSAY

* FUJIREBIO - ASSAY INTENDED TO IDENTIFY PATIENTS WHO MAY BENEFIT FROM TREATMENT WITH JANSSEN’S NEW INVESTIGATIONAL ORAL BACE INHIBITOR, ATABECESTAT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below